PsychoGenics

📣 PsychoGenics is proud to once again sponsor The Michael J. Fox Foundation for Parkinson's Research conference in NYC. 👋 If you’re attending, be sure to say hello to Drs. Sylvie Ramboz and Lisa Kretsge—we’re thrilled to have them representing us! www.psychogenics.com

🎤Shout out to Dr. Mark Urban for sharing his expertise earlier today on “Translational Strategies for Migraine Therapeutic Development” at the Pain Therapeutics Summit. We hope you had the chance to attend in person — if not, please feel free to reach out with any questions or thoughts. PsychoGenics is proud to support the advancement of pain research and grateful for the opportunity to participate in this year’s summit. www.psychogenics.com info@psychogenics.com Taleen Hanania

⁉️Attending the Pain Therapeutics Summit in San Diego this week⁉️ Be sure to stop by and say hello to Drs. Taleen Hanania & Mark Urban. AND don’t miss Dr. Urban’s session: 🧠“Translational Strategies for Migraine Therapeutic Development” 📅 Tuesday, October 14 🕥 10:20 am For any inquiries or to schedule a meeting, please contact us at info@psychogenics.com To learn more about our services visit our website: www.psychogenics.com.

PsychoGenics is a proud Sponsor of The Michael J. Fox Foundation for Parkinson's Research - Annual Parkinson's Disease Therapeutics Conference in New York City, October 15th & 16th. If you’re planning to attend, we invite you to connect with our team during the new Partnering Session on Thursday, October 15th. Take advantage of this networking opportunity to meet one on one with Drs. Sylvie Ramboz and Lisa Kretsge to discover how PsychoGenics can accelerate your research.   Reach out to us directly at info@psychogenics.com if you'd like to schedule a meeting.   For more information on PsychoGenics, please visit our website www.psychogenics.com.

💜 October marks Rett Syndrome Awareness Month—a time to honor the incredible strength of individuals living with this complex neurodevelopmental disorder and to reaffirm our commitment to finding effective treatments. This rare, severe genetic condition (caused primarily by the MECP2 mutation) necessitates urgent research for disease-modifying therapies to address profound deficits in movement, communication, and cognition.   At PsychoGenics, we are dedicated to supporting the global effort to translate genetic understanding into clinical success. We leverage our expertise in behavioral phenotyping and neurobiology to provide comprehensive preclinical services in the MECP2 mouse model of Rett Syndrome that include: Motor, cognitive, visual acuity and respiration assessments Seizure activity Efficacy & Safety Studies Biomarker Identification Long Term Potentiation We are proud to stand with the Rett Syndrome community and support the vital work of foundations driving advocacy and research. Let's work together to turn awareness into action.   To learn more about our specific preclinical models and services for Rett Syndrome, please visit our website: https://lnkd.in/eBRwCd-J

💜 October marks Rett Syndrome Awareness Month—a time to honor the incredible strength of individuals living with this complex neurodevelopmental disorder and to reaffirm our commitment to finding effective treatments. This rare, severe genetic condition (caused primarily by the MECP2 mutation) necessitates urgent research for disease-modifying therapies to address profound deficits in movement, communication, and cognition.   At PsychoGenics, we are dedicated to supporting the global effort to translate genetic understanding into clinical success. We leverage our expertise in behavioral phenotyping and neurobiology to provide comprehensive preclinical services in the MECP2 mouse model of Rett Syndrome that include: Motor, cognitive, visual acuity and respiration assessments Seizure activity Efficacy & Safety Studies Biomarker Identification Long Term Potentiation We are proud to stand with the Rett Syndrome community and support the vital work of foundations driving advocacy and research. Let's work together to turn awareness into action.   To learn more about our specific preclinical models and services for Rett Syndrome, please visit our website: https://lnkd.in/eBRwCd-J

🔬 Join us in San Diego on October 13 & 14 as PsychoGenics presents at the 19th Annual Pain Therapeutics Summit. Meet Drs. Mark Urban and Taleen Hanania during the Summit and be sure to attend Dr. Urban’s session, “Translational Strategies for Migraine Therapeutic Development,” at 10:20 a.m. on Tuesday, October 14. Stop by our booth to find out how PsychoGenics can assist with your preclinical pain research. For any inquiries or to schedule a meeting, please contact us at info@psychogenics.com To learn more about our services visit our website: www.psychogenics.com.

💜 September is Pain Awareness Month 💜 🔬 At PsychoGenics, we strive to be your strategic partner in developing novel pain therapies. In recognition of Pain Awareness Month, we are focused on helping you accelerate your pipeline with our validated preclinical models. Our comprehensive services are designed to deliver better translatable endpoints, providing the reliable, data-driven insights you need to confidently evaluate treatments for acute, osteoarthritic, neuropathic, and chronic pain. Our goal is to increase the reliability and predictive validity of your preclinical work, helping you identify promising candidates with a higher probability of clinical success. In the urgent search for effective, non-addictive treatments, our expert team is ready to design and execute studies tailored to your specific goals. Contact us today to discuss how PsychoGenics can advance your pain research program. Please visit our website to learn more about our preclinical pain models. https://lnkd.in/eCQ3D_Sy

💙As we observe Charcot-Marie-Tooth (CMT) Awareness Month, we want to share a glimpse into the work we're doing to make a difference in this community. At PsychoGenics, our mission extends beyond the lab; it is driven by a deep commitment to addressing challenging neurological disorders like CMT. Our collaborative partnership with the Charcot-Marie-Tooth Association (CMTA) is a powerful example of this commitment, and we are profoundly grateful for their leadership and tireless dedication. The CMTA's work—from funding pivotal research to providing invaluable support for patients and families—is absolutely essential to the progress being made in the field. By combining the CMTA's patient-focused vision with our expertise in preclinical drug development, we are working to accelerate the journey toward effective therapies. Together, we're leveraging advanced models and innovative techniques to gather the critical data necessary to move promising new treatments closer to clinical trials. Our joint efforts in characterizing models for CMT1A, CMT2A, and CMT2E underscore our shared dedication to pushing the boundaries of scientific discovery for everyone affected by CMT.

🔬 At PsychoGenics, we offer high-throughput quantitative immunohistochemistry (IHC) and histology services to evaluate and quantify standard and novel biomarkers of disease progression and treatment response. We have expertise in sectioning and staining all tissue types, including Formalin-Fixed Paraffin-Embedded (FFPE) and frozen brain and spinal cord from a variety of species, including rodent disease models and humans, using proprietary and novel antibodies.   Click the link below to learn more about these services and how we can support you in enhancing your research. https://lnkd.in/eCfeKZcn